Affiliation:
1. A.F.Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological Center
2. A.F.Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological Center; P.A.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Abstract
Currently, due to the dynamic development of surgical technologies, indications for organ-sparing treatment of kidney cancer are expanding. Acute kidney injury is a serious complication that leads to chronic kidney disease, increased postoperative mortality, deterioration of long-term functional outcomes, and increased hospitalization. At present, it is known that even a slight damage to kidneys or their impairment, presented by a decreased urine output and change in blood biochemical parameters, entails serious clinical consequences and is associated with a poor prognosis. Damaging factors, when the kidney is exposed, initially induce molecular changes, which entail the production of certain biomarkers, and only after that clinical aspects of kidney damage develop. The causes of acute kidney injury can be different, from specific renal disorders (acute interstitial nephritis, vascular and glomerular lesions, prerenal azotemia, obstructive disorders) to toxic damages, direct trauma and surgical treatment. The development of acute renal injury in the postoperative period is a serious complication of the surgical treatment of kidney disease, and, according to various authors, the frequency of its occurrence varies from 5.5 % to 34 %. An active study of this problem made it possible to find specific biomarkers that give the possibility to predict and diagnose acute renal injury in the early stages, to optimize the treatment strategy, to reduce the incidence of postoperative complications, and to shorten the period of postoperative rehabilitation. Currently, the most studied of acute kidney injury (AKI) biomarkers are cystatin C, neutrophil gelatinase-associated lipocalin‑2 (NGAL), hepatic protein L-FABP, KIM‑1 (Kidney injury molecule‑1), Interleukin – 18. Further study of AKI biomarkers will make it possible to determine the most significant ones for subsequent use in everyday practice
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference40 articles.
1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184. https://doi.org/10.1159/000339789
2. Miroshkina IV, Gritskevich AA, Baytman TP, Pyanikin SS, Arevin AG, Kalinin DV, et al. The role of markers of acute kidney damage in assessing kidney function with its ischemia. Experimental and Clinical Urology. 2018;(4):114–121. (In Russian).
3. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006 Aug 15;145(4):237–246. https://doi.org/10.7326/0003-4819-145-4-200608150-00003
4. Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39–48. https://doi.org/10.1007/BF03194597
5. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol. 2011 Jan;22(1):165–175. https://doi.org/10.1681/ASN.2010060641
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献